The first participants have been given the vaccine candidate, which is adjuvanted with Dynavax's CpG 1018 plus alum. About 22,000 participants who are 18 or older are expected to be enrolled in the trial across Latin America, Asia, Europe, and Africa. The study is fully funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and will make the vaccine available through the COVAX Facility upon regulatory approval.

Clover's Trimer-Tag drug development platform, which allows the production of novel, covalently-trimerized fusion proteins, was used to develop the recombinant spike protein-based vaccine candidate.

Interim analysis of the primary endpoint expected in the middle of 2021, according to the companies.

Dynavax helps advance COVID-19 vaccine candidates
Dynavax Technologies said it will be providing additional quantities of its CpG 1018 adjuvant for Valneva's SARS-CoV-2 vaccine candidate and has also...

Medigen Vaccine, Dynavax begin phase II trial for subunit COVID-19 vaccine
Medigen Vaccine Biologics and Dynavax Technologies have dosed the first participant in a phase II clinical trial evaluating Medigen's COVID-19 vaccine...

Cytiva helps Clover scale up biomanufacturing of COVID-19 vaccine
Clover Biopharmaceuticals is working with Cytiva to scale up the company's COVID-19 vaccine manufacturing capabilities.

Clover touts positive preclinical results for COVID-19 vaccine
Clover Biopharmaceuticals has announced positive preclinical data regarding its protein-based COVID-19 S-Trimer vaccine candidate in combination with...

Dynavax partners on Valneva's SARS-CoV-2 vaccine candidate
Dynavax will supply its CpG 1018 adjuvant for use in Valneva's SARS-CoV-2 vaccine candidate, VLA2001, as part of a commercial partnership.

CEPI expands Clover partnership on COVID-19 vaccine
The Coalition for Epidemic Prepardeness Innovations (CEPI) has expanded its partnership with Clover Biopharmaceuticals for the development and manufacture...